Takeda's Zasocitinib Delivers in Phase 3 for Hard-to-Treat Psoriasis
Takeda calls phase 3 results for oral TYK2 inhibitor zasocitinib 'top-notch' in difficult-to-treat psoriasis, positioning a pill against biologics.
Topic
Phase 3
Topic
Phase 3
Moderna, Merck Say mRNA Melanoma Vaccine Succeeded in Phase 3
Moderna and Merck say their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial — a first for the mRNA platfor…
Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension
Phase 3 extension data show denifanstat, an oral fatty acid synthase inhibitor, sustained acne improvement through 52 weeks — the…
Lebrikizumab Phase 3 Shows Symptom, Itch Gains in Pediatric AD
Phase 3 data show lebrikizumab improved atopic dermatitis symptoms and itch in children, extending IL-13 inhibition evidence into…
Merck Reports First Positive Phase 3 for Personalized mRNA Melanoma Therapy
Merck posts the first positive Phase 3 result for a personalized mRNA melanoma therapy, advancing individualized neoantigen immun…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trial
Phase 3 head-to-head data show once-daily zasocitinib achieved superior skin clearance versus deucravacitinib in plaque psoriasis…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Trial
Zasocitinib showed superior efficacy versus deucravacitinib in Phase 3 head-to-head psoriasis data, with rapid, durable clearance…
Barzolvolimab Hits All Phase 3 End Points in Chronic Spontaneous Urticaria
Barzolvolimab, a KIT-targeting monoclonal antibody, met all primary and secondary end points in a Phase 3 chronic spontaneous urt…
Regeneron Shares Fall as Skin Cancer Therapy Misses in Late-Stage Trial
Regeneron shares dropped after a skin cancer treatment failed a late-stage trial. Details on the drug, indication and endpoint pe…